AA
PTX

Ancora Advisors’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Ancora Advisors’s Portfolio PTX Stock Details PTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,700
Closed -$91K – 505
2014
Q1 		$91K Buy
+1,700
New +$56.1K 0.01% 432

Other funds holding PTX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return

Ancora Advisors's PTX Position: Q2 2014 in Review

Ancora Advisors sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q2 2014, closing a stake of 1,700 shares — an estimated $91K sold.

Ancora Advisors first reported a position in PTX in Q1 2014 and held it in 1 quarter. The position peaked at $91K in Q1 2014. 89 funds tracked by Wall St. Rank hold PTX as of Q2 2014.

  • Ancora Advisors reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q2 2014 after selling out during the quarter.
  • Ancora Advisors sold 1,700 Pernix Therapeutics Holdings, Inc. shares in Q2 2014, an estimated $91K.
  • Ancora Advisors first reported a position in Pernix Therapeutics Holdings, Inc. in Q1 2014 and held it in 1 quarter.
  • Ancora Advisors's Pernix Therapeutics Holdings, Inc. position peaked at $91K in Q1 2014.
  • 89 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q2 2014.

Based on Ancora Advisors's 13F filing for Q2 2014, filed 31 Jul 2014.